Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
Globe Newswire•20/08/2026•09:15 ET
0
Whiz Insights
All patients enrolled and treated across original and FDA-cleared expansion cohorts
Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain
Get started
Create a free account to read the full story.